Satellos Announces Promising Phase 1b Trial Results of SAT-3247 in Adults with Duchenne Muscular Dystrophy

Satellos Bioscience Inc., a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, recently announced promising Phase 1b data, in an open-label study treating five adult male DMD patients, ages 20 – 27, demonstrating early signs that SAT-3247 may have the potential to affect grip strength, which could represent a clinically meaningful measure for patients with DMD.

SAT-3247 is designed to address progressive muscle loss in DMD patients by aiming to restore regeneration in response to damage. The Phase 1b open-label trial of SAT-3247 was conducted in adults with DMD, with the primary endpoint being safety and tolerability.

Satellos is an alumnus of our CAAP® program and presented at the OBIO® Investment Summit.